메뉴 건너뛰기




Volumn 6, Issue , 2017, Pages 116-132

Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics

Author keywords

anti miR; ASGPR; ASO; GalNAc; liver targeted delivery; oligonucleotide; RNAi; siRNA

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ASIALOGLYCOPROTEIN RECEPTOR; MICRORNA; N ACETYLGALACTOSAMINE; NUCLEIC ACID; OLIGONUCLEOTIDE; SMALL INTERFERING RNA;

EID: 85015608983     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1016/j.omtn.2016.12.003     Document Type: Review
Times cited : (235)

References (123)
  • 1
    • 33751099034 scopus 로고    scopus 로고
    • RNAi therapeutics: a potential new class of pharmaceutical drugs
    • 1 Bumcrot, D., Manoharan, M., Koteliansky, V., Sah, D.W., RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2 (2006), 711–719.
    • (2006) Nat. Chem. Biol. , vol.2 , pp. 711-719
    • Bumcrot, D.1    Manoharan, M.2    Koteliansky, V.3    Sah, D.W.4
  • 2
    • 77957820261 scopus 로고    scopus 로고
    • RNAi and small interfering RNAs in human disease therapeutic applications
    • 2 Lares, M.R., Rossi, J.J., Ouellet, D.L., RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 28 (2010), 570–579.
    • (2010) Trends Biotechnol. , vol.28 , pp. 570-579
    • Lares, M.R.1    Rossi, J.J.2    Ouellet, D.L.3
  • 5
    • 84904901858 scopus 로고    scopus 로고
    • Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection
    • 5 Solano, E.C., Kornbrust, D.J., Beaudry, A., Foy, J.W., Schneider, D.J., Thompson, J.D., Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 24 (2014), 258–266.
    • (2014) Nucleic Acid Ther. , vol.24 , pp. 258-266
    • Solano, E.C.1    Kornbrust, D.J.2    Beaudry, A.3    Foy, J.W.4    Schneider, D.J.5    Thompson, J.D.6
  • 6
    • 84862173320 scopus 로고    scopus 로고
    • Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease
    • 6 Lee, D.U., Huang, W., Rittenhouse, K.D., Jessen, B., Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease. J. Ocul. Pharmacol. Ther. 28 (2012), 222–230.
    • (2012) J. Ocul. Pharmacol. Ther. , vol.28 , pp. 222-230
    • Lee, D.U.1    Huang, W.2    Rittenhouse, K.D.3    Jessen, B.4
  • 7
    • 84892741671 scopus 로고    scopus 로고
    • Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
    • 7 Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B.R., Sutherland, J.E., Hutabarat, R.M., Clausen, V.A., Karsten, V., Cehelsky, J., et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383 (2014), 60–68.
    • (2014) Lancet , vol.383 , pp. 60-68
    • Fitzgerald, K.1    Frank-Kamenetsky, M.2    Shulga-Morskaya, S.3    Liebow, A.4    Bettencourt, B.R.5    Sutherland, J.E.6    Hutabarat, R.M.7    Clausen, V.A.8    Karsten, V.9    Cehelsky, J.10
  • 10
    • 77952680862 scopus 로고    scopus 로고
    • Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
    • 10 Geisbert, T.W., Lee, A.C., Robbins, M., Geisbert, J.B., Honko, A.N., Sood, V., Johnson, J.C., de Jong, S., Tavakoli, I., Judge, A., et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375 (2010), 1896–1905.
    • (2010) Lancet , vol.375 , pp. 1896-1905
    • Geisbert, T.W.1    Lee, A.C.2    Robbins, M.3    Geisbert, J.B.4    Honko, A.N.5    Sood, V.6    Johnson, J.C.7    de Jong, S.8    Tavakoli, I.9    Judge, A.10
  • 12
    • 85013774429 scopus 로고    scopus 로고
    • 4LBA A phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis
    • 196–196
    • 12 Beg, M., Brenner, A., Sachdev, J., Borad, M., Cortes, J., Tibes, R., et al. 4LBA A phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis. Eur. J. Cancer, 50, 2014 196–196.
    • (2014) Eur. J. Cancer , vol.50
    • Beg, M.1    Brenner, A.2    Sachdev, J.3    Borad, M.4    Cortes, J.5    Tibes, R.6
  • 13
    • 84885065624 scopus 로고    scopus 로고
    • First microRNA mimic enters clinic
    • 13 Bouchie, A., First microRNA mimic enters clinic. Nat. Biotechnol., 31, 2013, 577.
    • (2013) Nat. Biotechnol. , vol.31 , pp. 577
    • Bouchie, A.1
  • 14
    • 85176869775 scopus 로고    scopus 로고
    • Mirna. (2016). Mirna Therapeutics Halts Phase 1 Clinical Study of MRX34.
    • 14 Mirna. (2016). Mirna Therapeutics Halts Phase 1 Clinical Study of MRX34. http://files.shareholder.com/downloads/AMDA-2PXH94/3644053911x0x908896/E5BD13E6-BF9E-4FA3-9651-B51597F7FC90/MIRN_News_2016_9_20_General_Releases.pdf.
  • 15
    • 84960852206 scopus 로고    scopus 로고
    • Drug developers refocus efforts on RAS
    • 15 Sheridan, C., Drug developers refocus efforts on RAS. Nat. Biotechnol. 34 (2016), 217–218.
    • (2016) Nat. Biotechnol. , vol.34 , pp. 217-218
    • Sheridan, C.1
  • 16
    • 80052468423 scopus 로고    scopus 로고
    • Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c
    • 16 Saad, F., Hotte, S., North, S., Eigl, B., Chi, K., Czaykowski, P., Wood, L., Pollak, M., Berry, S., Lattouf, J.B., et al., Canadian Uro-Oncology Group. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin. Cancer Res. 17 (2011), 5765–5773.
    • (2011) Clin. Cancer Res. , vol.17 , pp. 5765-5773
    • Saad, F.1    Hotte, S.2    North, S.3    Eigl, B.4    Chi, K.5    Czaykowski, P.6    Wood, L.7    Pollak, M.8    Berry, S.9    Lattouf, J.B.10
  • 19
    • 84958680040 scopus 로고    scopus 로고
    • Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease
    • 19 Monteleone, G., Di Sabatino, A., Ardizzone, S., Pallone, F., Usiskin, K., Zhan, X., Rossiter, G., Neurath, M.F., Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease. Aliment. Pharmacol. Ther. 43 (2016), 717–724.
    • (2016) Aliment. Pharmacol. Ther. , vol.43 , pp. 717-724
    • Monteleone, G.1    Di Sabatino, A.2    Ardizzone, S.3    Pallone, F.4    Usiskin, K.5    Zhan, X.6    Rossiter, G.7    Neurath, M.F.8
  • 20
    • 77949485460 scopus 로고    scopus 로고
    • Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
    • 20 Raal, F.J., Santos, R.D., Blom, D.J., Marais, A.D., Charng, M.J., Cromwell, W.C., Lachmann, R.H., Gaudet, D., Tan, J.L., Chasan-Taber, S., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375 (2010), 998–1006.
    • (2010) Lancet , vol.375 , pp. 998-1006
    • Raal, F.J.1    Santos, R.D.2    Blom, D.J.3    Marais, A.D.4    Charng, M.J.5    Cromwell, W.C.6    Lachmann, R.H.7    Gaudet, D.8    Tan, J.L.9    Chasan-Taber, S.10
  • 21
    • 84868518061 scopus 로고    scopus 로고
    • Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease
    • 21 Stein, E.A., Dufour, R., Gagne, C., Gaudet, D., East, C., Donovan, J.M., Chin, W., Tribble, D.L., McGowan, M., Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126 (2012), 2283–2292.
    • (2012) Circulation , vol.126 , pp. 2283-2292
    • Stein, E.A.1    Dufour, R.2    Gagne, C.3    Gaudet, D.4    East, C.5    Donovan, J.M.6    Chin, W.7    Tribble, D.L.8    McGowan, M.9
  • 22
    • 84995752459 scopus 로고    scopus 로고
    • Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line
    • 22 Dowling, J.J., Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line. Nat. Rev. Neurol. 12 (2016), 675–676.
    • (2016) Nat. Rev. Neurol. , vol.12 , pp. 675-676
    • Dowling, J.J.1
  • 23
    • 85176855127 scopus 로고    scopus 로고
    • Editorial (2016). Railroading at the FDA. Nat Biotechnol. 34, 1078.
    • 23 Editorial (2016). Railroading at the FDA. Nat Biotechnol. 34, 1078.
  • 24
    • 0025043480 scopus 로고
    • The asialoglycoprotein receptor: a model for endocytic transport receptors
    • 24 Spiess, M., The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry 29 (1990), 10009–10018.
    • (1990) Biochemistry , vol.29 , pp. 10009-10018
    • Spiess, M.1
  • 25
    • 0019130107 scopus 로고
    • Difficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte
    • 25 Schwartz, A.L., Rup, D., Lodish, H.F., Difficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte. J. Biol. Chem. 255 (1980), 9033–9036.
    • (1980) J. Biol. Chem. , vol.255 , pp. 9033-9036
    • Schwartz, A.L.1    Rup, D.2    Lodish, H.F.3
  • 26
    • 0028998769 scopus 로고
    • The asialoglycoprotein receptor: relationships between structure, function, and expression
    • 26 Stockert, R.J., The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol. Rev. 75 (1995), 591–609.
    • (1995) Physiol. Rev. , vol.75 , pp. 591-609
    • Stockert, R.J.1
  • 27
    • 34548267667 scopus 로고    scopus 로고
    • Endocytic mechanisms for targeted drug delivery
    • 27 Bareford, L.M., Swaan, P.W., Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 59 (2007), 748–758.
    • (2007) Adv. Drug Deliv. Rev. , vol.59 , pp. 748-758
    • Bareford, L.M.1    Swaan, P.W.2
  • 28
    • 63649163810 scopus 로고    scopus 로고
    • The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid alpha2,6-galactose
    • 28 Steirer, L.M., Park, E.I., Townsend, R.R., Baenziger, J.U., The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid alpha2,6-galactose. J. Biol. Chem. 284 (2009), 3777–3783.
    • (2009) J. Biol. Chem. , vol.284 , pp. 3777-3783
    • Steirer, L.M.1    Park, E.I.2    Townsend, R.R.3    Baenziger, J.U.4
  • 29
    • 0027293871 scopus 로고
    • Ca2+-dependent carbohydrate-recognition domains in animal proteins
    • 29 Drickamer, K., Ca2+-dependent carbohydrate-recognition domains in animal proteins. Curr. Opin. Struct. Biol. 3 (1993), 393–400.
    • (1993) Curr. Opin. Struct. Biol. , vol.3 , pp. 393-400
    • Drickamer, K.1
  • 30
    • 0034697981 scopus 로고    scopus 로고
    • Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor
    • 30 Meier, M., Bider, M.D., Malashkevich, V.N., Spiess, M., Burkhard, P., Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J. Mol. Biol. 300 (2000), 857–865.
    • (2000) J. Mol. Biol. , vol.300 , pp. 857-865
    • Meier, M.1    Bider, M.D.2    Malashkevich, V.N.3    Spiess, M.4    Burkhard, P.5
  • 31
    • 0019992236 scopus 로고
    • Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line
    • 31 Schwartz, A.L., Fridovich, S.E., Lodish, H.F., Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line. J. Biol. Chem. 257 (1982), 4230–4237.
    • (1982) J. Biol. Chem. , vol.257 , pp. 4230-4237
    • Schwartz, A.L.1    Fridovich, S.E.2    Lodish, H.F.3
  • 32
    • 0016322758 scopus 로고
    • The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins
    • 32 Ashwell, G., Morell, A.G., The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv. Enzymol. Relat. Areas Mol. Biol. 41 (1974), 99–128.
    • (1974) Adv. Enzymol. Relat. Areas Mol. Biol. , vol.41 , pp. 99-128
    • Ashwell, G.1    Morell, A.G.2
  • 33
    • 0017622966 scopus 로고
    • Uptake and degradation of 125I-labelled asialo-fetuin by isolated rat hepatocytes
    • 33 Tolleshaug, H., Berg, T., Nilsson, M., Norum, K.R., Uptake and degradation of 125I-labelled asialo-fetuin by isolated rat hepatocytes. Biochim. Biophys. Acta 499 (1977), 73–84.
    • (1977) Biochim. Biophys. Acta , vol.499 , pp. 73-84
    • Tolleshaug, H.1    Berg, T.2    Nilsson, M.3    Norum, K.R.4
  • 34
    • 0018746767 scopus 로고
    • Coated pits, coated vesicles, and receptor-mediated endocytosis
    • 34 Goldstein, J.L., Anderson, R.G., Brown, M.S., Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature 279 (1979), 679–685.
    • (1979) Nature , vol.279 , pp. 679-685
    • Goldstein, J.L.1    Anderson, R.G.2    Brown, M.S.3
  • 36
    • 0018366405 scopus 로고
    • Intracellular localization and degradation of asialofetuin in isolated rat hepatocytes
    • 36 Tolleshaug, H., Berg, T., Frölich, W., Norum, K.R., Intracellular localization and degradation of asialofetuin in isolated rat hepatocytes. Biochim. Biophys. Acta 585 (1979), 71–84.
    • (1979) Biochim. Biophys. Acta , vol.585 , pp. 71-84
    • Tolleshaug, H.1    Berg, T.2    Frölich, W.3    Norum, K.R.4
  • 37
    • 0019159338 scopus 로고
    • Galactose and N-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes
    • 37 Baenziger, J.U., Fiete, D., Galactose and N-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes. Cell 22 (1980), 611–620.
    • (1980) Cell , vol.22 , pp. 611-620
    • Baenziger, J.U.1    Fiete, D.2
  • 38
    • 0023212742 scopus 로고
    • Receptor-mediated in vitro gene transformation by a soluble DNA carrier system
    • 38 Wu, G.Y., Wu, C.H., Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem. 262 (1987), 4429–4432.
    • (1987) J. Biol. Chem. , vol.262 , pp. 4429-4432
    • Wu, G.Y.1    Wu, C.H.2
  • 39
    • 0023811723 scopus 로고
    • Receptor-mediated gene delivery and expression in vivo
    • 39 Wu, G.Y., Wu, C.H., Receptor-mediated gene delivery and expression in vivo. J. Biol. Chem. 263 (1988), 14621–14624.
    • (1988) J. Biol. Chem. , vol.263 , pp. 14621-14624
    • Wu, G.Y.1    Wu, C.H.2
  • 40
    • 0024282306 scopus 로고
    • Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro
    • 40 Wu, G.Y., Wu, C.H., Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro. Biochemistry 27 (1988), 887–892.
    • (1988) Biochemistry , vol.27 , pp. 887-892
    • Wu, G.Y.1    Wu, C.H.2
  • 41
    • 0026952599 scopus 로고
    • Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand
    • 41 Plank, C., Zatloukal, K., Cotten, M., Mechtler, K., Wagner, E., Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand. Bioconjug. Chem. 3 (1992), 533–539.
    • (1992) Bioconjug. Chem. , vol.3 , pp. 533-539
    • Plank, C.1    Zatloukal, K.2    Cotten, M.3    Mechtler, K.4    Wagner, E.5
  • 43
    • 0026688793 scopus 로고
    • Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides
    • 43 Wu, G.Y., Wu, C.H., Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J. Biol. Chem. 267 (1992), 12436–12439.
    • (1992) J. Biol. Chem. , vol.267 , pp. 12436-12439
    • Wu, G.Y.1    Wu, C.H.2
  • 44
    • 0029401589 scopus 로고
    • Cell-type specific and ligand specific enhancement of cellular uptake of oligodeoxynucleoside methylphosphonates covalently linked with a neoglycopeptide, YEE(ah-GalNAc)3
    • 44 Hangeland, J.J., Levis, J.T., Lee, Y.C., Ts'o, P.O., Cell-type specific and ligand specific enhancement of cellular uptake of oligodeoxynucleoside methylphosphonates covalently linked with a neoglycopeptide, YEE(ah-GalNAc)3. Bioconjug. Chem. 6 (1995), 695–701.
    • (1995) Bioconjug. Chem. , vol.6 , pp. 695-701
    • Hangeland, J.J.1    Levis, J.T.2    Lee, Y.C.3    Ts'o, P.O.4
  • 46
    • 7444229247 scopus 로고    scopus 로고
    • Design and synthesis of novel N-acetylgalactosamine-terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor
    • 46 Rensen, P.C., van Leeuwen, S.H., Sliedregt, L.A., van Berkel, T.J., Biessen, E.A., Design and synthesis of novel N-acetylgalactosamine-terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor. J. Med. Chem. 47 (2004), 5798–5808.
    • (2004) J. Med. Chem. , vol.47 , pp. 5798-5808
    • Rensen, P.C.1    van Leeuwen, S.H.2    Sliedregt, L.A.3    van Berkel, T.J.4    Biessen, E.A.5
  • 47
    • 0033559540 scopus 로고    scopus 로고
    • A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2
    • 47 Rohlff, C., Watson, S.A., Morris, T.M., Skelton, L., Jackman, A.L., Page, M.J., A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2. Cancer Res. 59 (1999), 1268–1272.
    • (1999) Cancer Res. , vol.59 , pp. 1268-1272
    • Rohlff, C.1    Watson, S.A.2    Morris, T.M.3    Skelton, L.4    Jackman, A.L.5    Page, M.J.6
  • 49
    • 77955684788 scopus 로고    scopus 로고
    • Lactosaminated human albumin, a hepatotropic carrier of drugs
    • 49 Fiume, L., Di Stefano, G., Lactosaminated human albumin, a hepatotropic carrier of drugs. Eur. J. Pharm. Sci. 40 (2010), 253–262.
    • (2010) Eur. J. Pharm. Sci. , vol.40 , pp. 253-262
    • Fiume, L.1    Di Stefano, G.2
  • 50
    • 0029935180 scopus 로고    scopus 로고
    • Selective sugar binding to the carbohydrate recognition domains of the rat hepatic and macrophage asialoglycoprotein receptors
    • 50 Iobst, S.T., Drickamer, K., Selective sugar binding to the carbohydrate recognition domains of the rat hepatic and macrophage asialoglycoprotein receptors. J. Biol. Chem. 271 (1996), 6686–6693.
    • (1996) J. Biol. Chem. , vol.271 , pp. 6686-6693
    • Iobst, S.T.1    Drickamer, K.2
  • 51
    • 0035813160 scopus 로고    scopus 로고
    • Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo
    • 51 Rensen, P.C., Sliedregt, L.A., Ferns, M., Kieviet, E., van Rossenberg, S.M., van Leeuwen, S.H., van Berkel, T.J., Biessen, E.A., Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J. Biol. Chem. 276 (2001), 37577–37584.
    • (2001) J. Biol. Chem. , vol.276 , pp. 37577-37584
    • Rensen, P.C.1    Sliedregt, L.A.2    Ferns, M.3    Kieviet, E.4    van Rossenberg, S.M.5    van Leeuwen, S.H.6    van Berkel, T.J.7    Biessen, E.A.8
  • 52
    • 43049125473 scopus 로고    scopus 로고
    • Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor
    • 52 Khorev, O., Stokmaier, D., Schwardt, O., Cutting, B., Ernst, B., Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor. Bioorg. Med. Chem. 16 (2008), 5216–5231.
    • (2008) Bioorg. Med. Chem. , vol.16 , pp. 5216-5231
    • Khorev, O.1    Stokmaier, D.2    Schwardt, O.3    Cutting, B.4    Ernst, B.5
  • 53
    • 0019190912 scopus 로고
    • Human hepatic lectin. Physiochemical properties and specificity
    • 53 Baenziger, J.U., Maynard, Y., Human hepatic lectin. Physiochemical properties and specificity. J. Biol. Chem. 255 (1980), 4607–4613.
    • (1980) J. Biol. Chem. , vol.255 , pp. 4607-4613
    • Baenziger, J.U.1    Maynard, Y.2
  • 54
    • 0021099058 scopus 로고
    • Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features
    • 54 Lee, Y.C., Townsend, R.R., Hardy, M.R., Lönngren, J., Arnarp, J., Haraldsson, M., Lönn, H., Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features. J. Biol. Chem. 258 (1983), 199–202.
    • (1983) J. Biol. Chem. , vol.258 , pp. 199-202
    • Lee, Y.C.1    Townsend, R.R.2    Hardy, M.R.3    Lönngren, J.4    Arnarp, J.5    Haraldsson, M.6    Lönn, H.7
  • 56
    • 84938056583 scopus 로고    scopus 로고
    • Asialoglycoprotein Receptor and Its Application in Liver-targeted Drug Delivery
    • 56 Huang, Y.Y., Liang, Z.C., Asialoglycoprotein Receptor and Its Application in Liver-targeted Drug Delivery. Prog Biochem Biophys 42 (2015), 501–510.
    • (2015) Prog Biochem Biophys , vol.42 , pp. 501-510
    • Huang, Y.Y.1    Liang, Z.C.2
  • 59
    • 85176836684 scopus 로고    scopus 로고
    • Rajeev, K.G.Zimmermann, T., Manoharan, M., Maier., M., Kuchimanchi, S., and Charisse, K. (2013). Modified RNAi agents. U.S. Patent WO2013074974.
    • 59 Rajeev, K.G.Zimmermann, T., Manoharan, M., Maier., M., Kuchimanchi, S., and Charisse, K. (2013). Modified RNAi agents. U.S. Patent WO2013074974.
  • 63
    • 85176868621 scopus 로고    scopus 로고
    • Alnylam. (2014). Advances in Delivery of RNAi Therapeutics with Enhanced Stabilization Chemistry (ESC)-GalNAc-siRNA Conjugates.
    • 63 Alnylam. (2014). Advances in Delivery of RNAi Therapeutics with Enhanced Stabilization Chemistry (ESC)-GalNAc-siRNA Conjugates. http://www.alnylam.com/web/assets/Roundtable_ESC-GalNAc-Conjugates_072214.pdf.
  • 66
    • 84990304685 scopus 로고    scopus 로고
    • Pre-Clinical Evaluation of ALN-AAT to Ameliorate Liver Disease Associated With Alpha-1-Antitrypsin Deficiency
    • 66 Sehgal, A., Blomenkamp, K.S., Qian, K., Simon, A., Haslett, P., Barros, S., et al. Pre-Clinical Evaluation of ALN-AAT to Ameliorate Liver Disease Associated With Alpha-1-Antitrypsin Deficiency. Gastroenterology, 148, 2015, S-975.
    • (2015) Gastroenterology , vol.148 , pp. S-975
    • Sehgal, A.1    Blomenkamp, K.S.2    Qian, K.3    Simon, A.4    Haslett, P.5    Barros, S.6
  • 68
    • 79959624824 scopus 로고    scopus 로고
    • Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2
    • 68 Ferdinandi, E.S., Vassilakos, A., Lee, Y., Lightfoot, J., Fitsialos, D., Wright, J.A., Young, A.H., Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2. Cancer Chemother. Pharmacol. 68 (2011), 193–205.
    • (2011) Cancer Chemother. Pharmacol. , vol.68 , pp. 193-205
    • Ferdinandi, E.S.1    Vassilakos, A.2    Lee, Y.3    Lightfoot, J.4    Fitsialos, D.5    Wright, J.A.6    Young, A.H.7
  • 69
    • 84987630012 scopus 로고    scopus 로고
    • Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic
    • 69 Moreno, P.M., Pêgo, A.P., Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front Chem., 2, 2014, 87.
    • (2014) Front Chem. , vol.2 , pp. 87
    • Moreno, P.M.1    Pêgo, A.P.2
  • 70
    • 85176862829 scopus 로고    scopus 로고
    • Alnylam. (2015). Alnylam R&D Day.
    • 70 Alnylam. (2015). Alnylam R&D Day. http://files.shareholder.com/downloads/ABEA-430HSO/1862527561x0x865960/B08F6EC1-4FF6-48AD-A2E3-8CB626DE3B5D/RD_Day_2015_Full_Day_FINALnapdf.
  • 71
    • 84937764228 scopus 로고    scopus 로고
    • An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
    • 71 Sehgal, A., Barros, S., Ivanciu, L., Cooley, B., Qin, J., Racie, T., Hettinger, J., Carioto, M., Jiang, Y., Brodsky, J., et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat. Med. 21 (2015), 492–497.
    • (2015) Nat. Med. , vol.21 , pp. 492-497
    • Sehgal, A.1    Barros, S.2    Ivanciu, L.3    Cooley, B.4    Qin, J.5    Racie, T.6    Hettinger, J.7    Carioto, M.8    Jiang, Y.9    Brodsky, J.10
  • 72
    • 84985041005 scopus 로고    scopus 로고
    • Emerging drugs for the treatment of hemophilia A and B
    • 72 Morfini, M., Zanon, E., Emerging drugs for the treatment of hemophilia A and B. Expert Opin. Emerg. Drugs 21 (2016), 301–313.
    • (2016) Expert Opin. Emerg. Drugs , vol.21 , pp. 301-313
    • Morfini, M.1    Zanon, E.2
  • 73
    • 85015675094 scopus 로고    scopus 로고
    • NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY
    • 73 Strat, A.L., Ghiciuc, C.M., Lupuşoru, C.E., Mitu, F., NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY. Rev. Med. Chir. Soc. Med. Nat. Iasi 120 (2016), 228–232.
    • (2016) Rev. Med. Chir. Soc. Med. Nat. Iasi , vol.120 , pp. 228-232
    • Strat, A.L.1    Ghiciuc, C.M.2    Lupuşoru, C.E.3    Mitu, F.4
  • 74
    • 84960330442 scopus 로고    scopus 로고
    • Novel therapies for severe dyslipidemia originating from human genetics
    • 74 Gaudet, D., Novel therapies for severe dyslipidemia originating from human genetics. Curr. Opin. Lipidol. 27 (2016), 112–124.
    • (2016) Curr. Opin. Lipidol. , vol.27 , pp. 112-124
    • Gaudet, D.1
  • 75
    • 84991827712 scopus 로고    scopus 로고
    • A subcutaneously administered investigational RNAi therapeutic (ALN-CC5) targeting complement C5 for treatment of PNH and complement-mediated diseases: interim Phase 1 study results
    • 75 Hill, A., Taubel, J., Bush, J., Borodovsky, A., Kawahata, N., McLean, H., Powell, C., Chaturvedi, P., Warner, G., Garg, P., et al. A subcutaneously administered investigational RNAi therapeutic (ALN-CC5) targeting complement C5 for treatment of PNH and complement-mediated diseases: interim Phase 1 study results. Blood, 126, 2015, 2413.
    • (2015) Blood , vol.126 , pp. 2413
    • Hill, A.1    Taubel, J.2    Bush, J.3    Borodovsky, A.4    Kawahata, N.5    McLean, H.6    Powell, C.7    Chaturvedi, P.8    Warner, G.9    Garg, P.10
  • 77
    • 84982908689 scopus 로고    scopus 로고
    • Stones: A novel RNAi therapy for PH1
    • 77 Carney, E.F., Stones: A novel RNAi therapy for PH1. Nat. Rev. Nephrol., 12, 2016, 508.
    • (2016) Nat. Rev. Nephrol. , vol.12 , pp. 508
    • Carney, E.F.1
  • 78
    • 84991579783 scopus 로고    scopus 로고
    • Aiming for cure in HBV and HDV infection
    • 78 Petersen, J., Thompson, A.J., Levrero, M., Aiming for cure in HBV and HDV infection. J. Hepatol. 65 (2016), 835–848.
    • (2016) J. Hepatol. , vol.65 , pp. 835-848
    • Petersen, J.1    Thompson, A.J.2    Levrero, M.3
  • 79
    • 84938521049 scopus 로고    scopus 로고
    • Progress and prospects of anti-HBV gene therapy development
    • 79 Maepa, M.B., Roelofse, I., Ely, A., Arbuthnot, P., Progress and prospects of anti-HBV gene therapy development. Int. J. Mol. Sci. 16 (2015), 17589–17610.
    • (2015) Int. J. Mol. Sci. , vol.16 , pp. 17589-17610
    • Maepa, M.B.1    Roelofse, I.2    Ely, A.3    Arbuthnot, P.4
  • 82
    • 84929574453 scopus 로고    scopus 로고
    • siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes
    • 82 Matsuda, S., Keiser, K., Nair, J.K., Charisse, K., Manoharan, R.M., Kretschmer, P., Peng, C.G., V Kel'in, A., Kandasamy, P., Willoughby, J.L., et al. siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem. Biol. 10 (2015), 1181–1187.
    • (2015) ACS Chem. Biol. , vol.10 , pp. 1181-1187
    • Matsuda, S.1    Keiser, K.2    Nair, J.K.3    Charisse, K.4    Manoharan, R.M.5    Kretschmer, P.6    Peng, C.G.7    V Kel'in, A.8    Kandasamy, P.9    Willoughby, J.L.10
  • 84
    • 84870570270 scopus 로고    scopus 로고
    • Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo
    • 84 Wong, S.C., Klein, J.J., Hamilton, H.L., Chu, Q., Frey, C.L., Trubetskoy, V.S., Hegge, J., Wakefield, D., Rozema, D.B., Lewis, D.L., Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther. 22 (2012), 380–390.
    • (2012) Nucleic Acid Ther. , vol.22 , pp. 380-390
    • Wong, S.C.1    Klein, J.J.2    Hamilton, H.L.3    Chu, Q.4    Frey, C.L.5    Trubetskoy, V.S.6    Hegge, J.7    Wakefield, D.8    Rozema, D.B.9    Lewis, D.L.10
  • 85
    • 84955349803 scopus 로고    scopus 로고
    • Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes
    • 85 Sebestyén, M.G., Wong, S.C., Trubetskoy, V., Lewis, D.L., Wooddell, C.I., Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes. Methods Mol. Biol. 1218 (2015), 163–186.
    • (2015) Methods Mol. Biol. , vol.1218 , pp. 163-186
    • Sebestyén, M.G.1    Wong, S.C.2    Trubetskoy, V.3    Lewis, D.L.4    Wooddell, C.I.5
  • 87
  • 90
    • 85176865832 scopus 로고    scopus 로고
    • Arrowhead. (2016). Arrowhead Pharmaceuticals Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521.
    • 90 Arrowhead. (2016). Arrowhead Pharmaceuticals Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521. http://files.shareholder.com/downloads/AMDA-2OTJP1/1862504966x0x907254/5730467A-2DC8-4079-97B0-195D1A96B95A/ARWR_News_2016_9_7_General_Releases.pdf.
  • 91
    • 85176851067 scopus 로고    scopus 로고
    • Dicerna. (2016). Welcome to Investor Day.
    • 91 Dicerna. (2016). Welcome to Investor Day. http://files.shareholder.com/downloads/AMDA-2IH3D0/3375799178x0x898098/D565497C-DCC6-40C5-91C7-60C010D9A346/DicernaInvestorDayJune292016.pdf.
  • 92
    • 85006071413 scopus 로고    scopus 로고
    • A single subcutaneous dose of 2 mg/kg or 4 mg/kg of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against miR-122, results in significant viral load reductions in chronic hepatitis C patients
    • 92 Van der Ree, M., de Vree, M.L., Stelma, F., Willemse, S., van der Valk, M., Rietdijk, S., Molenkamp, R., Schinkel, J., Hadi, S., Harbers, M., et al. A single subcutaneous dose of 2 mg/kg or 4 mg/kg of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against miR-122, results in significant viral load reductions in chronic hepatitis C patients. J. Hepatol., 62, 2015, S261.
    • (2015) J. Hepatol. , vol.62 , pp. S261
    • Van der Ree, M.1    de Vree, M.L.2    Stelma, F.3    Willemse, S.4    van der Valk, M.5    Rietdijk, S.6    Molenkamp, R.7    Schinkel, J.8    Hadi, S.9    Harbers, M.10
  • 94
    • 84905584822 scopus 로고    scopus 로고
    • Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
    • 94 Prakash, T.P., Graham, M.J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H.F., et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42 (2014), 8796–8807.
    • (2014) Nucleic Acids Res. , vol.42 , pp. 8796-8807
    • Prakash, T.P.1    Graham, M.J.2    Yu, J.3    Carty, R.4    Low, A.5    Chappell, A.6    Schmidt, K.7    Zhao, C.8    Aghajan, M.9    Murray, H.F.10
  • 95
    • 84864199342 scopus 로고    scopus 로고
    • Structure and nuclease resistance of 2′,4′-constrained 2′-O-methoxyethyl (cMOE) and 2′-O-ethyl (cEt) modified DNAs
    • 95 Pallan, P.S., Allerson, C.R., Berdeja, A., Seth, P.P., Swayze, E.E., Prakash, T.P., Egli, M., Structure and nuclease resistance of 2′,4′-constrained 2′-O-methoxyethyl (cMOE) and 2′-O-ethyl (cEt) modified DNAs. Chem. Commun. (Camb.) 48 (2012), 8195–8197.
    • (2012) Chem. Commun. (Camb.) , vol.48 , pp. 8195-8197
    • Pallan, P.S.1    Allerson, C.R.2    Berdeja, A.3    Seth, P.P.4    Swayze, E.E.5    Prakash, T.P.6    Egli, M.7
  • 96
    • 84962171168 scopus 로고    scopus 로고
    • Comprehensive structure-activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes
    • 96 Prakash, T.P., Yu, J., Migawa, M.T., Kinberger, G.A., Wan, W.B., Østergaard, M.E., Carty, R.L., Vasquez, G., Low, A., Chappell, A., et al. Comprehensive structure-activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes. J. Med. Chem. 59 (2016), 2718–2733.
    • (2016) J. Med. Chem. , vol.59 , pp. 2718-2733
    • Prakash, T.P.1    Yu, J.2    Migawa, M.T.3    Kinberger, G.A.4    Wan, W.B.5    Østergaard, M.E.6    Carty, R.L.7    Vasquez, G.8    Low, A.9    Chappell, A.10
  • 98
  • 99
    • 85015678091 scopus 로고    scopus 로고
    • Potent antisense oligonucleotides to Apo(a) normalize plasma LP(a) levels in the majority of people with elevated LP(a): results of ISIS-APO(a)Rx Phase 2 and ISIS-APO(a)-LRx Phase 1 trials
    • 99 Viney, N., Marcovina, S., Xia, S.T., Geary, R., Witztum, J., Tsimikas, S., Potent antisense oligonucleotides to Apo(a) normalize plasma LP(a) levels in the majority of people with elevated LP(a): results of ISIS-APO(a)Rx Phase 2 and ISIS-APO(a)-LRx Phase 1 trials. J. Am. Coll. Cardiol., 67, 2016, 2081.
    • (2016) J. Am. Coll. Cardiol. , vol.67 , pp. 2081
    • Viney, N.1    Marcovina, S.2    Xia, S.T.3    Geary, R.4    Witztum, J.5    Tsimikas, S.6
  • 100
    • 85015610805 scopus 로고    scopus 로고
    • Future Therapy for HBV: Role of Cell Cycle Inhibitors
    • 100 Brahmania, M., Janssen, H.L.A., Future Therapy for HBV: Role of Cell Cycle Inhibitors. Curr. Hepatol. Rep., 15, 2016, 245.
    • (2016) Curr. Hepatol. Rep. , vol.15 , pp. 245
    • Brahmania, M.1    Janssen, H.L.A.2
  • 101
    • 84992193857 scopus 로고    scopus 로고
    • Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities
    • 101 Boucle, S., Bassit, L., Ehteshami, M., Schinazi, R.F., Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities. Clin. Liver Dis. 20 (2016), 737–749.
    • (2016) Clin. Liver Dis. , vol.20 , pp. 737-749
    • Boucle, S.1    Bassit, L.2    Ehteshami, M.3    Schinazi, R.F.4
  • 103
  • 108
    • 84949782714 scopus 로고    scopus 로고
    • Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides
    • 108 Yamamoto, T., Sawamura, M., Wada, F., Harada-Shiba, M., Obika, S., Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides. Bioorg. Med. Chem. 24 (2016), 26–32.
    • (2016) Bioorg. Med. Chem. , vol.24 , pp. 26-32
    • Yamamoto, T.1    Sawamura, M.2    Wada, F.3    Harada-Shiba, M.4    Obika, S.5
  • 110
    • 85176828553 scopus 로고    scopus 로고
    • Alnylam. (2015). Next generation LDL-C management with ALN-PCSsc, an investigational PCSK9 synthesis inhibitor.
    • 110 Alnylam. (2015). Next generation LDL-C management with ALN-PCSsc, an investigational PCSK9 synthesis inhibitor. http://www.themedicinescompany.com/sites/default/files/pdf/ALNY-MDCO_PCSsc_AnalystCallSlides_30Aug2015.pdf.
  • 111
    • 85176872573 scopus 로고    scopus 로고
    • Alnylam. (2016). 2016 RNAi Roundtable: Fitusiran for the Treatment of Hemophilia and Rare Bleeding Disorders.
    • 111 Alnylam. (2016). 2016 RNAi Roundtable: Fitusiran for the Treatment of Hemophilia and Rare Bleeding Disorders. http://files.shareholder.com/downloads/ABEA-430HSO/3338525009x0x905556/3A9C92BE-BD18-49E8-A730-E481B07D4264/Fitusiran_Roundtable_102216.pdf.
  • 112
    • 85176832531 scopus 로고    scopus 로고
    • Alnylam. (2016). 2016 RNAi Roundtable: ALN-CC5 for the Treatment of Complement-Mediated Diseases.
    • 112 Alnylam. (2016). 2016 RNAi Roundtable: ALN-CC5 for the Treatment of Complement-Mediated Diseases. http://files.shareholder.com/downloads/ABEA-430HSO/3338525009x0x906527/4976772E-32FD-4A18-9D57-34BECB083692/ALN-CC5_Roundtable_FINAL2_083116.pdf.
  • 113
    • 85176872878 scopus 로고    scopus 로고
    • Alnylam. (2016). 2016 RNAi Roundtable: ALN-GO1 for the treatment of primary hyperoxaluria type 1 (PH1).
    • 113 Alnylam. (2016). 2016 RNAi Roundtable: ALN-GO1 for the treatment of primary hyperoxaluria type 1 (PH1). http://files.shareholder.com/downloads/ABEA-430HSO/3338525009x0x909656/3EAC5FE3-E62C-4BC1-B95E-01084BB7288F/GO1_Roundtable_Slides_092716_Final2.pdf.
  • 114
    • 85176857192 scopus 로고    scopus 로고
    • Alnylam. (2016). 2016 RNAi Roundtable: ALN-HBV for the treatment of hepatitis B virus (HBV) infection.
    • 114 Alnylam. (2016). 2016 RNAi Roundtable: ALN-HBV for the treatment of hepatitis B virus (HBV) infection. http://files.shareholder.com/downloads/ABEA-430HSO/3338525009x0x911299/25B3A016-2BCC-4AC3-B494-5A35E2FE5F9D/ALN-HBV_Roundtable_Slides.FINAL.v3.pdf.
  • 115
    • 85176826051 scopus 로고    scopus 로고
    • Alnylam. (2016). 2016 RNAi Roundtable: ALN-AS1 for the treatment of acute hepatic porphyrias.
    • 115 Alnylam. (2016). 2016 RNAi Roundtable: ALN-AS1 for the treatment of acute hepatic porphyrias. http://files.shareholder.com/downloads/ABEA-430HSO/3338525009x0x907951/C29D1F9A-55A8-49B8-A3F6-7443191C759B/ALN-AS1_Roundtable_FINAL_091316.pdf.
  • 116
    • 85176821863 scopus 로고    scopus 로고
    • Alnylam. (2015). Enhanced Pharmacologic Activity and Durability Demonstrated with an ESC GalNAc-siRNA Targeting Transthyretin.
    • 116 Alnylam. (2015). Enhanced Pharmacologic Activity and Durability Demonstrated with an ESC GalNAc-siRNA Targeting Transthyretin. http://www.alnylam.com/web/assets/ALN-TTRsc02_OTS_101415.pdf.
  • 117
    • 84861092456 scopus 로고    scopus 로고
    • First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice
    • 117 Pol, S., Lampertico, P., First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice. J. Viral Hepat. 19 (2012), 377–386.
    • (2012) J. Viral Hepat. , vol.19 , pp. 377-386
    • Pol, S.1    Lampertico, P.2
  • 118
    • 18344369543 scopus 로고    scopus 로고
    • MicroRNA biogenesis: coordinated cropping and dicing
    • 118 Kim, V.N., MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 6 (2005), 376–385.
    • (2005) Nat. Rev. Mol. Cell Biol. , vol.6 , pp. 376-385
    • Kim, V.N.1
  • 119
    • 33845755467 scopus 로고    scopus 로고
    • Illuminating the silence: understanding the structure and function of small RNAs
    • 119 Rana, T.M., Illuminating the silence: understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell Biol. 8 (2007), 23–36.
    • (2007) Nat. Rev. Mol. Cell Biol. , vol.8 , pp. 23-36
    • Rana, T.M.1
  • 120
    • 77951168054 scopus 로고    scopus 로고
    • Breaking down the barriers: siRNA delivery and endosome escape
    • 120 Dominska, M., Dykxhoorn, D.M., Breaking down the barriers: siRNA delivery and endosome escape. J. Cell Sci. 123 (2010), 1183–1189.
    • (2010) J. Cell Sci. , vol.123 , pp. 1183-1189
    • Dominska, M.1    Dykxhoorn, D.M.2
  • 121
    • 84954099191 scopus 로고    scopus 로고
    • RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?
    • 121 Bobbin, M.L., Rossi, J.J., RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?. Annu. Rev. Pharmacol. Toxicol. 56 (2016), 103–122.
    • (2016) Annu. Rev. Pharmacol. Toxicol. , vol.56 , pp. 103-122
    • Bobbin, M.L.1    Rossi, J.J.2
  • 123
    • 84856431819 scopus 로고    scopus 로고
    • RNA therapeutics: beyond RNA interference and antisense oligonucleotides
    • 123 Kole, R., Krainer, A.R., Altman, S., RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 11 (2012), 125–140.
    • (2012) Nat. Rev. Drug Discov. , vol.11 , pp. 125-140
    • Kole, R.1    Krainer, A.R.2    Altman, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.